Physician profile
Luca Pauselli
NPI 1811457591
$1,143.45
in general payments reported to CMS, 2019-2025
13 companies · $897 in 2025
The $897 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $247 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.45 | 2025 | |
| Janssen Pharmaceuticals, INC | $226.02 | 2024-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $104.67 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Gilead Sciences, INC. | $86.18 | 2025 | Yeztugo |
| Alkermes, INC. | $83.67 | 2024-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $74.04 | 2024-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $51.50 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $51.47 | 2025 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.80 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $35.93 | 2025 | Austedo Xr |
| Sage Therapeutics, LLC | $18.29 | 2025 | Zurzuvae |
| Neos Therapeutics, LP | $17.95 | 2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $15.48 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luca Pauselli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.